Earnings Call Summary | Nutex Health(NUTX.US) Q2 2024 Earnings Conference
Earnings Call Summary | Nutex Health(NUTX.US) Q2 2024 Earnings Conference
The following is a summary of the Nutex Health (NUTX) Q2 2024 Earnings Call Transcript:
以下是Nutex Health（NUTX）Q2 2024業績會議呼叫記錄摘要：
Financial Performance:
金融業績：
Q2 2024 total revenue grew 29%, from $58.9 million to $76.1 million year-over-year.
Mature hospital revenue increased by 13.2% compared to Q2 2023.
Hospital division visits increased by 28% compared to the same quarter last year.
Gross profit for Q2 2024 was $22.6 million, a 134% increase over Q2 2023, representing a margin of 29.7%.
Adjusted EBITDA for Q2 2024 was $12 million, an increase of 200% compared to $4 million in Q2 2023.
Net loss improved significantly from $3.5 million in Q2 2023 to only $364,000 in Q2 2024.
Q2 2024總營業收入同比增長29％，從5,890萬美元增至7,610萬美元。
與Q2 2023相比，成熟醫院的收入增長了13.2％。
醫院部門的就診人數同比增長28％。
Q2 2024的毛利潤爲2260萬美元，較Q2 2023增長134％，佔比29.7％。
Q2 2024調整後的EBITDA爲1200萬美元，較Q2 2023增長200％，爲400萬美元。
淨虧損從Q2 2023的350萬美元顯着好轉，僅爲Q2 2024的364,000美元。
Business Progress:
業務進展：
Nutex Health is expanding with four new hospitals under construction, expected to open in the next 6-12 months in various locations including Idaho, Florida, Wisconsin, and Texas.
Planning to open one to three new hospitals per year beyond 2025.
Sold off less profitable assets to reinvest in more strategic areas.
Implemented a new HR software, Workday, to streamline operations and planning to introduce new labor management software.
Nutex Health正在擴張，並正在建設四家新醫院，預計在接下來的6-12個月內在不同的地點，包括愛達荷州、佛羅里達州、威斯康星州和德克薩斯州開業。
計劃在2025年後每年開設一至三家新醫院。
出售利潤較低的資產以重新投資更具戰略性的領域。
實施了新的人力資源軟件Workday，以簡化運營，並計劃引入新的勞動力管理軟件。
Opportunities:
機會：
Positioned to meet the growing demand for healthcare, especially with an aging population ('silver tsunami').
Expanding the service mix at hospitals to increase inpatient and observation volumes, aiming for more comprehensive care within their facilities.
準備滿足不斷增長的醫療需求，特別是隨着人口老齡化而來的「白銀海嘯」。
擴大醫院的服務組合，增加住院和觀察量，並旨在在其設施內提供更全面的護理。
Risks:
風險：
Arbitration process under the No Surprises Act could affect revenue if unsuccessful, despite previous favorable outcomes.
如果不成功，未來費用不得超過限額法仲裁程序可能會影響收入，儘管以前有過有利的結果。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。